SBIR Phase I: Development and Characterization of Bio-inert UNCD films for Implantable Devices to Eliminate Blood Clotting

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0912855
Agency Tracking Number: 0912855
Amount: $99,852.00
Phase: Phase I
Program: SBIR
Awards Year: 2009
Solicitation Year: N/A
Solicitation Topic Code: BC
Solicitation Number: NSF 08-548
Small Business Information
429 B Weber Road, # 286, Romeoville, IL, 60446
DUNS: 143371388
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 John Carlisle
 (815) 293-0900
Business Contact
 John Carlisle
Title: PhD
Phone: (815) 293-0900
Research Institution
This Small Business Innovation Research Phase I project will investigate UNCDýý, a nanocrystalline from of smooth, thin diamond, as an anti-thrombotic coating for implantable medical devices. One of the largest problem with implantable circulatory assist devices such as artificial hearts and vascular assist devices (VADs) is the need to treat patients with anticoagulants to avoid blood clots within the devices and to avoid heart attack, stroke, and death that may occur if the anticoagulation dosage is not right. Previous work on diamond and diamond-like carbon (DLC) has demonstrated reduced interactivity between the coating and human blood clotting factors. The use of UNCD however, with its overall biochemical and electrochemical inertness, extreme durability to wear, and very low surface roughness, will extend the advantages previously demonstrated with other carbon materials. The broader impacts of this research are the potential reduction or elimination of anticoagulants for patients with implanted medical devices, making a much larger patient population eligible for advanced devices such as heart pumps, and enabling the use of these devices for new applications. UNCD coatings on the blood contacting surfaces of these and similar devices has the potential to eliminate the need for anticoagulation or to reduce it to so low a dose that the risk of fatal bleeding can be eliminated. The reduction in prescription costs alone could pay for this investment many times over. Fundamental work will also shed light on the effects of dynamic blood flow, variations in surface chemistry and morphology on the thrombus/clot formation. This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government